These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11904959)

  • 41. [Herceptin and its therapeutic strategy in patients with breast cancer overexpressing HER2].
    Tajima T; Suzuki Y; Tokuda Y
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1132-7. PubMed ID: 12145992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What's so special about [symbol: see text] trastuzumab?
    Drug Ther Bull; 2002 Sep; 40(9):65-7. PubMed ID: 12298222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.
    Lazaridis G; Pentheroudakis G; Pavlidis N
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):31-41. PubMed ID: 17766143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
    Smith IE
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
    Haq B; Geyer CE
    Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From HER2 to herceptin.
    Mokbel K; Hassanally D
    Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
    Yeon CH; Pegram MD
    Invest New Drugs; 2005 Oct; 23(5):391-409. PubMed ID: 16133791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. What can we learn from Herceptin trials in metastatic breast cancer?
    Bell R
    Oncology; 2002; 63 Suppl 1():39-46. PubMed ID: 12422054
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical practice-changing trials: the HERA study paradigm.
    Zardavas D; Ades F; de Azambuja E
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1249-56. PubMed ID: 24138446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospect for anti-HER2 receptor therapy in breast cancer.
    Brand FX; Ravanel N; Gauchez AS; Pasquier D; Payan R; Fagret D; Mousseau M
    Anticancer Res; 2006; 26(1B):463-70. PubMed ID: 16739306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 56. HER-2-targeted therapy: lessons learned and future directions.
    Nahta R; Esteva FJ
    Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.
    Baker JH; Lindquist KE; Huxham LA; Kyle AH; Sy JT; Minchinton AI
    Clin Cancer Res; 2008 Apr; 14(7):2171-9. PubMed ID: 18381959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 59. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
    Meric-Bernstam F; Hung MC
    Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The HER2 World: Better Treatment Selection for Better Outcome.
    Tagliabue E; Campiglio M; Pupa SM; Balsari A; Ménard S
    J Natl Cancer Inst Monogr; 2011; 2011(43):82-5. PubMed ID: 22043048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.